Hydrogel-Mediated DOX⋅HCl/PTX Delivery System for Breast Cancer Therapy

Hydrogel-Mediated DOX⋅HCl/PTX Delivery System for Breast Cancer Therapy

We used a hydrogel-mediated dual drug delivery approach, based on an injectable glycol chitosan (GC) hydrogel, doxorubicin hydrochloride (DOX⋅HCl), and a complex of beta-cyclodextrin (β-CD) and paclitaxel (PTX) (GDCP) for breast cancer therapy in vitro and in vivo. The hydrogel was swollen over 3 da...

Full description

Bibliographic Details
Main Authors: Hoon Hyun, Young Bum Yoo, So Yeon Kim, Hyun Sun Ko, Heung Jae Chun, Dae Hyeok Yang
Format: Article
Language:English
Published: MDPI AG 2019-09-01
Series:International Journal of Molecular Sciences
Subjects:
injectable glycol chitosan
doxorubicin hydrochloride
beta-cyclodextrin
paclitaxel
breast cancer therapy
Online Access:https://www.mdpi.com/1422-0067/20/19/4671
id doaj-e13b7878061141cc8ea365fe7ee9ae81
record_format Article
spelling doaj-e13b7878061141cc8ea365fe7ee9ae812020-11-25T02:08:00ZengMDPI AGInternational Journal of Molecular Sciences1422-00672019-09-012019467110.3390/ijms20194671ijms20194671Hydrogel-Mediated DOX⋅HCl/PTX Delivery System for Breast Cancer TherapyHoon Hyun0Young Bum Yoo1So Yeon Kim2Hyun Sun Ko3Heung Jae Chun4Dae Hyeok Yang5Department of Biomedical Sciences, Chonnam National University Medical School, Gwangju 61469, KoreaDepartment of Surgery, School of Medicine, Konkuk University, Seoul 05030, KoreaDepartment of Dental Hygiene, College of Health Sciences, Cheongju University, Cheongju 28503, KoreaDepartment of Obstetrics & Gynecology, College of Medicine, The Catholic University of Korea, Seoul 06591, KoreaDepartment of Medical Life Sciences, College of Medicine, The Catholic University of Korea, Seoul 06591, KoreaInstitute of Cell and Tissue Engineering, College of Medicine, The Catholic University of Korea, Seoul 06591, KoreaWe used a hydrogel-mediated dual drug delivery approach, based on an injectable glycol chitosan (GC) hydrogel, doxorubicin hydrochloride (DOX⋅HCl), and a complex of beta-cyclodextrin (β-CD) and paclitaxel (PTX) (GDCP) for breast cancer therapy in vitro and in vivo. The hydrogel was swollen over 3 days and remained so thereafter. After an initial burst period of 7 hours, the two drugs were released in a sustained manner for 7 days. The in vitro cell viability test showed that GDCP had a better anticancer effect than well plate and DOX⋅HCl/PTX (DP). In addition, the in vivo tests, which evaluated the anticancer effect, systemic toxicity, and histology, proved the feasibility of GDCP as a clinical therapy for breast cancer.https://www.mdpi.com/1422-0067/20/19/4671injectable glycol chitosandoxorubicin hydrochloridebeta-cyclodextrinpaclitaxelbreast cancer therapy
collection DOAJ
language English
format Article
sources DOAJ
author Hoon Hyun
Young Bum Yoo
So Yeon Kim
Hyun Sun Ko
Heung Jae Chun
Dae Hyeok Yang
spellingShingle Hoon Hyun
Young Bum Yoo
So Yeon Kim
Hyun Sun Ko
Heung Jae Chun
Dae Hyeok Yang
Hydrogel-Mediated DOX⋅HCl/PTX Delivery System for Breast Cancer Therapy
International Journal of Molecular Sciences
injectable glycol chitosan
doxorubicin hydrochloride
beta-cyclodextrin
paclitaxel
breast cancer therapy
author_facet Hoon Hyun
Young Bum Yoo
So Yeon Kim
Hyun Sun Ko
Heung Jae Chun
Dae Hyeok Yang
author_sort Hoon Hyun
title Hydrogel-Mediated DOX⋅HCl/PTX Delivery System for Breast Cancer Therapy
title_short Hydrogel-Mediated DOX⋅HCl/PTX Delivery System for Breast Cancer Therapy
title_full Hydrogel-Mediated DOX⋅HCl/PTX Delivery System for Breast Cancer Therapy
title_fullStr Hydrogel-Mediated DOX⋅HCl/PTX Delivery System for Breast Cancer Therapy
title_full_unstemmed Hydrogel-Mediated DOX⋅HCl/PTX Delivery System for Breast Cancer Therapy
title_sort hydrogel-mediated dox⋅hcl/ptx delivery system for breast cancer therapy
publisher MDPI AG
series International Journal of Molecular Sciences
issn 1422-0067
publishDate 2019-09-01
description We used a hydrogel-mediated dual drug delivery approach, based on an injectable glycol chitosan (GC) hydrogel, doxorubicin hydrochloride (DOX⋅HCl), and a complex of beta-cyclodextrin (β-CD) and paclitaxel (PTX) (GDCP) for breast cancer therapy in vitro and in vivo. The hydrogel was swollen over 3 days and remained so thereafter. After an initial burst period of 7 hours, the two drugs were released in a sustained manner for 7 days. The in vitro cell viability test showed that GDCP had a better anticancer effect than well plate and DOX⋅HCl/PTX (DP). In addition, the in vivo tests, which evaluated the anticancer effect, systemic toxicity, and histology, proved the feasibility of GDCP as a clinical therapy for breast cancer.
topic injectable glycol chitosan
doxorubicin hydrochloride
beta-cyclodextrin
paclitaxel
breast cancer therapy
url https://www.mdpi.com/1422-0067/20/19/4671
work_keys_str_mv AT hoonhyun hydrogelmediateddoxhclptxdeliverysystemforbreastcancertherapy
AT youngbumyoo hydrogelmediateddoxhclptxdeliverysystemforbreastcancertherapy
AT soyeonkim hydrogelmediateddoxhclptxdeliverysystemforbreastcancertherapy
AT hyunsunko hydrogelmediateddoxhclptxdeliverysystemforbreastcancertherapy
AT heungjaechun hydrogelmediateddoxhclptxdeliverysystemforbreastcancertherapy
AT daehyeokyang hydrogelmediateddoxhclptxdeliverysystemforbreastcancertherapy
_version_ 1724928150818783232

Similar Items